ReviewWorld journal of gastrointestinal oncology2021
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Review in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Risk Factors of Incidental Cholangiocarcinoma in Primary Sclerosing Cholangitis: A Cross-Sectional Study with ROC Curve Analysis.Archives of Iranian medicine · 2026Article
- Genetic architecture of primary sclerosing cholangitis: shared pathways with inflammatory bowel disease and gut-liver axis mediation.International journal of surgery (London, England) · 2026Article
- Epidemiology, comorbidities, treatments and outcomes of autoimmune liver diseases: A French nationwide study.JHEP reports : innovation in hepatology · 2025Article
- Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- Ethical Considerations and Equipoise in Cancer Surgery.Indian journal of surgical oncology · 2024Review
- Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease.World journal of gastroenterology · 2024Review
- Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives.Hepatobiliary surgery and nutrition · 2024Article
- Case report: The diagnostic dilemma of indeterminate biliary strictures: report on two cases with a literature review.Frontiers in oncology · 2024Article
- Role of routine lymph node dissection alongside resection of intrahepatic cholangiocarcinoma: Systematic review and meta-analysis.World journal of gastrointestinal oncology · 2023Article
- Epidermal growth factor rs4444903 polymorphism and risk of cholangiocarcinoma. A case control study.Clinical and experimental hepatology · 2023Article
- Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances.World journal of gastroenterology · 2023Review
- Pancreaticoduodenectomy After Liver Transplantation: A Single-Center Experience.World journal of surgery · 2023Review
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- Stereotactic radiotherapy for intrahepatic cholangiocarcinoma.World journal of gastrointestinal oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a premalignant condition and a well-documented risk factor for cholangiocarcinoma (CCA) which is the most common malignancy in this setting and the leading cause of deaths in the recent years, with an increasing incidence. PSC-associated CCA has a geographical distribution that follows the incidence of PSC, with an observed ascending gradient from the Eastern to the Western and from the Southern to the Northern countries. It may arise at any location along the biliary tree but is most common in the perihilar area. Patients with PSC and intrahepatic or perihilar CCA are typically not suitable for liver resection, which is otherwise the treatment of choice with curative intent in patients with resectable tumours, providing a radical resection with clear margins can be achieved. This largely relates to the commonly advanced stage of liver disease at presentation, which allows consideration for liver resection only for a very limited number of suitable patients with PSC. On the other hand, remarkable progress has been reached in the last decades with the implementation of a protocol combining neoadjuvant chemoradiation and orthotopic liver transplantation (OLT) for the treatment of perihilar CCA, within specific criteria. Excellent results have been achieved particularly for PSC patients with this cancer, who seem to benefit the most from this treatment, having converted this into an accepted indication for transplantation and the standard of care in several experienced centres. Intrahepatic CCA as an indication for OLT remains controversial and has not been accepted given disappointing previous results. However, as recent studies have shown favourable outcomes in early intrahepatic CCA, it may be that under defined criteria, OLT may play a more prominent role in the future. Distal CCA in the context of PSC requires aggressive surgical treatment with curative intent, when feasible. This review provides insight about particular features of CCA in the setting of PSC, with a main focus on its incidence, considerations relating to its anatomical location and implications to treatment and outcomes, through the viewpoint of historical evolution of management, and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.